Last reviewed · How we verify
MK-0524B
MK-0524B is a glucagon receptor antagonist.
MK-0524B is a glucagon receptor antagonist. Used for Type 2 diabetes.
At a glance
| Generic name | MK-0524B |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Glucagon receptor antagonist |
| Target | Glucagon receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Glucagon receptor antagonists work by blocking the action of glucagon, a hormone that raises blood glucose levels. By inhibiting glucagon's effects, MK-0524B aims to improve glycemic control in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
- MK-0524B Lipid Study (MK-0524B-063) (PHASE3)
- Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143) (PHASE3)
- Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024) (PHASE3)
- A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118) (PHASE3)
- Lipid Efficacy Study (0524B-022)(COMPLETED) (PHASE3)
- MK0524B Bioequivalence Study (0524B-070) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |